📊 VVOS Key Takeaways
Is Vivos Therapeutics, Inc. (VVOS) a Good Investment?
Vivos Therapeutics is in severe financial distress with negative stockholders' equity (-$1.1M), a critical liquidity crisis (0.27x current ratio), and unsustainable cash burn of $6M annually against only $2.1M in cash reserves, implying sub-5-month runway. While gross margins of 59.5% demonstrate product viability, the company loses $1.51 for every dollar of revenue with deep operating losses (-128.7% margin) and cannot service its obligations.
Vivos Therapeutics, Inc. Key Strengths (VVOS)
- Healthy gross margin of 59.5% indicates product/service quality and pricing power
- Revenue growth of 16% YoY shows some market traction despite financial distress
- Minimal capital expenditure requirements ($18K) suggests asset-light business model
VVOS Stock Risks: Vivos Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$1.1M indicates technical insolvency and existential solvency risk
- Critical liquidity crisis with current ratio of 0.27x; liabilities exceed current assets by 73%
- Cash runway of approximately 4-5 months at current $6M annual operating cash burn rate with only $2.1M in cash
- Operating losses of $6.6M on $5.1M revenue indicate unsustainable unit economics requiring immediate restructuring
- Negative operating cash flow of -$6M vastly exceeds revenue, unsustainable without capital infusion or dramatic cost reduction
Key Metrics to Watch
- Cash balance trend and monthly burn rate (critical solvency indicator)
- Operating cash flow and path to breakeven (company must dramatically reduce losses)
- Revenue growth sustainability and gross profit expansion (must offset operating expenses)
- Debt covenant compliance and refinancing needs (bankruptcy risk if breached)
- Insider transaction patterns (Form 4 filings may signal management confidence or distress)
Vivos Therapeutics, Inc. (VVOS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VVOS Profit Margin, ROE & Profitability Analysis
VVOS vs Healthcare Sector: How Vivos Therapeutics, Inc. Compares
How Vivos Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vivos Therapeutics, Inc. Stock Overvalued? VVOS Valuation Analysis 2026
Based on fundamental analysis, Vivos Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vivos Therapeutics, Inc. Balance Sheet: VVOS Debt, Cash & Liquidity
VVOS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vivos Therapeutics, Inc.'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $-2.22 indicates the company is currently unprofitable.
VVOS Revenue Growth, EPS Growth & YoY Performance
VVOS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.0M | -$3.9M | $-0.45 |
| Q3 2025 | $3.9M | -$1.9M | $-0.40 |
| Q2 2025 | $3.8M | -$1.9M | $-0.55 |
| Q1 2025 | $3.0M | -$3.8M | $-0.45 |
| Q3 2024 | $3.3M | -$1.7M | $-0.40 |
| Q2 2024 | $3.4M | -$1.7M | $-0.60 |
| Q1 2024 | $3.4M | -$1.7M | $-1.63 |
| Q3 2023 | $3.3M | -$1.7M | $-1.75 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vivos Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VVOS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vivos Therapeutics, Inc. (CIK: 0001716166)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VVOS
What is the AI rating for VVOS?
Vivos Therapeutics, Inc. (VVOS) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VVOS's key strengths?
Claude: Healthy gross margin of 59.5% indicates product/service quality and pricing power. Revenue growth of 16% YoY shows some market traction despite financial distress.
What are the risks of investing in VVOS?
Claude: Negative stockholders' equity of -$1.1M indicates technical insolvency and existential solvency risk. Critical liquidity crisis with current ratio of 0.27x; liabilities exceed current assets by 73%.
What is VVOS's revenue and growth?
Vivos Therapeutics, Inc. reported revenue of $5.1M.
Does VVOS pay dividends?
Vivos Therapeutics, Inc. does not currently pay dividends.
Where can I find VVOS SEC filings?
Official SEC filings for Vivos Therapeutics, Inc. (CIK: 0001716166) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VVOS's EPS?
Vivos Therapeutics, Inc. has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VVOS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vivos Therapeutics, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VVOS stock overvalued or undervalued?
Valuation metrics for VVOS: ROE of N/A (sector avg: 15%), net margin of -149.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VVOS's AI grade for 2026?
Our dual AI analysis gives Vivos Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VVOS's free cash flow?
Vivos Therapeutics, Inc.'s operating cash flow is $-6.0M, with capital expenditures of $18.0K. FCF margin is -117.3%.
How does VVOS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -149.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.27 (avg: 2).